{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:11:02Z","timestamp":1790701862882,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Endocrinology & Metabolism"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.tem.2020.02.002","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T04:36:29Z","timestamp":1583728589000},"page":"435-447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Inositols in Polycystic Ovary Syndrome: An Overview on the Advances"],"prefix":"10.1016","volume":"31","author":[{"given":"Fabio","family":"Facchinetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Unfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Dewailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdravko A.","family":"Kamenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Diamanti-Kandarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Simone","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Nestler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe O.","family":"Soulage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2020.02.002_bb0005","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/anie.201502227","article-title":"The \"other\" inositols and their phosphates: synthesis, biology, and medicine (with recent advances in myo-inositol chemistry)","volume":"55","author":"Thomas","year":"2016","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.tem.2020.02.002_bb0010","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/j.1471-4159.1987.tb05682.x","article-title":"Immunohistochemical staining and enzyme activity measurements show myo-inositol-1-phosphate synthase to be localized in the vasculature of brain","volume":"48","author":"Wong","year":"1987","journal-title":"J. Neurochem."},{"key":"10.1016\/j.tem.2020.02.002_bb0015","doi-asserted-by":"crossref","first-page":"11710","DOI":"10.1016\/S0021-9258(19)70191-4","article-title":"Stereochemistry of the myo-inositol-1-phosphate synthase reaction","volume":"255","author":"Loewus","year":"1980","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tem.2020.02.002_bb0020","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1968450","article-title":"Inositols in insulin signaling and glucose metabolism","volume":"2018","author":"Bevilacqua","year":"2018","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0025","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1080\/17425255.2016.1206887","article-title":"Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease","volume":"12","author":"Bizzarri","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.tem.2020.02.002_bb0030","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.tem.2018.09.001","article-title":"Inositol in polycystic ovary syndrome: restoring fertility through a pathophysiology-based approach","volume":"29","author":"Lagana","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.tem.2020.02.002_bb0035","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1507\/endocrj.EJ13-0423","article-title":"Decreased myo-inositol to chiro-inositol (M\/C) ratios and increased M\/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls","volume":"61","author":"Heimark","year":"2014","journal-title":"Endocr. J."},{"key":"10.1016\/j.tem.2020.02.002_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09513590.2016.1247797","article-title":"Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients","volume":"33","author":"Monastra","year":"2017","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0045","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1177\/1933719113518985","article-title":"Hyperinsulinemia alters myoinositol to d-chiroinositol ratio in the follicular fluid of patients with PCOS","volume":"21","author":"Unfer","year":"2014","journal-title":"Reprod. Sci."},{"key":"10.1016\/j.tem.2020.02.002_bb0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-319-23865-4_13","article-title":"The ratio of MI to DCI and its impact in the treatment of polycystic ovary syndrome: experimental and literature evidences","volume":"3","author":"Facchinetti","year":"2016","journal-title":"Front. Gynecol. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0055","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/jcph.362","article-title":"The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome","volume":"54","author":"Dinicola","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.tem.2020.02.002_bb0060","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/09513590.2015.1054802","article-title":"Reflections on inositol(s) for PCOS therapy: steps toward success","volume":"31","author":"Nestler","year":"2015","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0065","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3109\/09513590.2016.1144741","article-title":"Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives","volume":"32","author":"Paul","year":"2016","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0070","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1849162","article-title":"Effects of inositol(s) in women with PCOS: a systematic review of randomized controlled trials","volume":"2016","author":"Unfer","year":"2016","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0075","doi-asserted-by":"crossref","first-page":"6991","DOI":"10.1074\/jbc.M111.335539","article-title":"Regulation of insulin signaling and glucose transporter 4 (GLUT4) exocytosis by phosphatidylinositol 3,4,5-trisphosphate (PIP3) phosphatase, skeletal muscle, and kidney enriched inositol polyphosphate phosphatase (SKIP)","volume":"287","author":"Ijuin","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tem.2020.02.002_bb0080","first-page":"47","article-title":"D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance","volume":"3","author":"Larner","year":"2002","journal-title":"Int. J. Exp. Diabetes Res."},{"key":"10.1016\/j.tem.2020.02.002_bb0085","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJM199904293401703","article-title":"Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome","volume":"340","author":"Nestler","year":"1999","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.tem.2020.02.002_bb0090","doi-asserted-by":"crossref","DOI":"10.1186\/s12958-016-0189-2","article-title":"Modulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol","volume":"14","author":"Sacchi","year":"2016","journal-title":"Reprod. Biol. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0095","first-page":"2001","article-title":"Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system","volume":"83","author":"Nestler","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2020.02.002_bb0100","first-page":"10575","article-title":"D-chiro-inositol's action as aromatase inhibitor: rationale and potential clinical targets","volume":"23","author":"Lagana","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.tem.2020.02.002_bb0105","first-page":"5491","article-title":"Can high levels of D-chiro-inositol in follicular fluid exert detrimental effects on blastocyst quality?","volume":"21","author":"Ravanos","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.tem.2020.02.002_bb0110","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1095\/biolreprod.109.076760","article-title":"Involvement of phospholipase C-related inactive protein in the mouse reproductive system through the regulation of gonadotropin levels","volume":"81","author":"Matsuda","year":"2009","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.tem.2020.02.002_bb0115","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/molehr\/5.5.441","article-title":"Presence and dynamic redistribution of type I inositol 1,4,5-trisphosphate receptors in human oocytes and embryos during in-vitro maturation, fertilization and early cleavage divisions","volume":"5","author":"Goud","year":"1999","journal-title":"Mol. Hum. Reprod."},{"key":"10.1016\/j.tem.2020.02.002_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mehy.2016.03.014","article-title":"Does myo-inositol effect on PCOS follicles involve cytoskeleton regulation?","volume":"91","author":"Bizzarri","year":"2016","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.tem.2020.02.002_bb0125","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1210\/me.2010-0297","article-title":"FSH and its second messenger cAMP stimulate the transcription of human anti-Mullerian hormone in cultured granulosa cells","volume":"25","author":"Taieb","year":"2011","journal-title":"Mo. Endocrinol. (Baltimore, MD)"},{"key":"10.1016\/j.tem.2020.02.002_bb0130","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1677\/joe.1.06448","article-title":"Inositol triphosphate participates in an oestradiol nongenomic signalling pathway involved in accelerated oviductal transport in cycling rats","volume":"188","author":"Orihuela","year":"2006","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0135","article-title":"Inositols in the treatment of insulin-mediated diseases","volume":"2016","author":"Muscogiuri","year":"2016","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0140","doi-asserted-by":"crossref","first-page":"9387","DOI":"10.1002\/jcp.27623","article-title":"Myo-inositol and D-chiro-inositol (40:1) reverse histological and functional features of polycystic ovary syndrome in a mouse model","volume":"234","author":"Bevilacqua","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.tem.2020.02.002_bb0145","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1210\/en.2014-1196","article-title":"Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models","volume":"155","author":"Caldwell","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.tem.2020.02.002_bb0150","first-page":"1158","article-title":"Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries","volume":"79","author":"Gilling-Smith","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2020.02.002_bb0155","first-page":"5512","article-title":"The 40:1 myo-inositol\/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios","volume":"23","author":"Nordio","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.tem.2020.02.002_bb0160","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/j.fertnstert.2011.05.027","article-title":"The D-chiro-inositol paradox in the ovary","volume":"95","author":"Carlomagno","year":"2011","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.tem.2020.02.002_bb0165","first-page":"209","article-title":"Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth","volume":"68","author":"Harwood","year":"2007","journal-title":"Horm. Res."},{"key":"10.1016\/j.tem.2020.02.002_bb0170","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00404-006-0171-x","article-title":"Polycystic ovary syndrome: etiology and pathogenesis","volume":"274","author":"Matalliotakis","year":"2006","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.tem.2020.02.002_bb0175","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/humrep\/deh609","article-title":"Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries","volume":"20","author":"Rice","year":"2005","journal-title":"Hum. Reprod. (Oxford, England)"},{"key":"10.1016\/j.tem.2020.02.002_bb0180","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1530\/EC-17-0243","article-title":"Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials","volume":"6","author":"Unfer","year":"2017","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.tem.2020.02.002_bb0185","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/09513590.2012.743020","article-title":"Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study","volume":"29","author":"Artini","year":"2013","journal-title":"Gynecological Endocrinology"},{"key":"10.1016\/j.tem.2020.02.002_bb0190","first-page":"105","article-title":"Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial","volume":"13","author":"Costantino","year":"2009","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.tem.2020.02.002_bb0195","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/09513590801893232","article-title":"Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome","volume":"24","author":"Genazzani","year":"2008","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0200","first-page":"347","article-title":"Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS","volume":"11","author":"Gerli","year":"2007","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.tem.2020.02.002_bb0205","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/09513590.2013.860120","article-title":"Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS","volume":"30","author":"Pizzo","year":"2014","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0210","first-page":"575","article-title":"The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone","volume":"16","author":"Nordio","year":"2012","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.tem.2020.02.002_bb0215","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3204083","article-title":"A combined therapy with myo-inositol and D-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women","volume":"2016","author":"Benelli","year":"2016","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0220","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1473612","article-title":"Myo-inositol in the treatment of teenagers affected by PCOS","volume":"2016","author":"Pkhaladze","year":"2016","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0225","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1080\/09513590.2017.1296127","article-title":"Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial","volume":"33","author":"Emekci Ozay","year":"2017","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0230","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12020-017-1442-y","article-title":"Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis","volume":"59","author":"Zeng","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.tem.2020.02.002_bb0235","first-page":"1664","article-title":"A comparative study of myo inositol versus metformin on biochemical profile in polycystic ovarian syndrome in women","volume":"8","author":"Nehra","year":"2017","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"10.1016\/j.tem.2020.02.002_bb0240","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/09513590.2016.1236078","article-title":"Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS)","volume":"33","author":"Fruzzetti","year":"2017","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0245","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1530\/EJE-11-0840","article-title":"Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome","volume":"166","author":"Dona","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0250","first-page":"151","article-title":"Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial","volume":"7","author":"Gerli","year":"2003","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.tem.2020.02.002_bb0255","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.steroids.2013.04.004","article-title":"Cancer risk and PCOS","volume":"78","author":"Dumesic","year":"2013","journal-title":"Steroids"},{"key":"10.1016\/j.tem.2020.02.002_bb0260","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/1940-6207.CAPR-11-0536","article-title":"Metformin reduces endogenous reactive oxygen species and associated DNA damage","volume":"5","author":"Algire","year":"2012","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"10.1016\/j.tem.2020.02.002_bb0265","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8671762","article-title":"Insulin-sensitizers, polycystic ovary syndrome and gynaecological cancer risk","volume":"2016","author":"Lauretta","year":"2016","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0270","series-title":"Opinion: Inositol","author":"Select Committee on GRAS Substances (SCOGS)","year":"2017"},{"key":"10.1016\/j.tem.2020.02.002_bb0275","first-page":"931","article-title":"Inositol safety: clinical evidences","volume":"15","author":"Carlomagno","year":"2011","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.tem.2020.02.002_bb0280","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00404-018-5005-0","article-title":"Inositol for the prevention of gestational diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"299","author":"Vitagliano","year":"2019","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.tem.2020.02.002_bb0285","article-title":"Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes","volume":"2015","author":"Crawford","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tem.2020.02.002_bb0290","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/09513590.2018.1540578","article-title":"Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials","volume":"35","author":"Facchinetti","year":"2019","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0295","first-page":"189","article-title":"A comparative study of metabolic and hormonal effects of myoinositol vs. metformin in women with polycystic ovary syndrome: a randomised controlled trial","volume":"4","author":"Angik","year":"2015","journal-title":"Int. J. Reprod. Contracept Obstet. Gynecol."},{"key":"10.1016\/j.tem.2020.02.002_bb0300","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/cen.13366","article-title":"Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: a randomized controlled clinical trial","volume":"87","author":"Jamilian","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0305","first-page":"1","article-title":"A combined treatment with myo-inositol and monacolin k improve the androgen and lipid profiles of insulin-resistant PCOS patients","volume":"2","author":"De Leo","year":"2013","journal-title":"J Metabolic Synd."},{"key":"10.1016\/j.tem.2020.02.002_bb0310","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/cen.13304","article-title":"Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study","volume":"86","author":"Tagliaferri","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0315","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/09513590.2018.1549656","article-title":"Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial","volume":"35","author":"Agrawal","year":"2019","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0320","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.mehy.2012.01.009","article-title":"Oocyte quality reflected by follicular fluid analysis in poly cystic ovary syndrome (PCOS): a hypothesis based on intermediates of energy metabolism","volume":"78","author":"Arya","year":"2012","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.tem.2020.02.002_bb0325","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/09513590.2017.1421632","article-title":"The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review","volume":"34","author":"Gateva","year":"2018","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0330","series-title":"Controversies in Obstetrics, Gynecology and Infertility","first-page":"23","article-title":"A novel approach for treating infertile patients with diminished ovarian reserve (DOR)","author":"Carlomagno","year":"2011"},{"key":"10.1016\/j.tem.2020.02.002_bb0335","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00404-018-4861-y","article-title":"Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials","volume":"298","author":"Lagana","year":"2018","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.tem.2020.02.002_bb0340","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.fertnstert.2007.09.041","article-title":"Consensus on infertility treatment related to polycystic ovary syndrome","volume":"89","author":"Thessaloniki EA-SPCWG-Sponsored PCOS Consensus Workshop Group","year":"2008","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.tem.2020.02.002_bb0345","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/09513590.2014.964640","article-title":"Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance","volume":"31","author":"Kamenov","year":"2015","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0350","first-page":"10","article-title":"Could myo-inositol soft gel capsules outperform clomiphene in inducing ovulation? Results of a pilot study","volume":"21","author":"Rolland","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.tem.2020.02.002_bb0355","article-title":"Inositol for subfertile women with polycystic ovary syndrome","volume":"12","author":"Showell","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tem.2020.02.002_bb0360","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.febslet.2015.03.012","article-title":"Inositol transport proteins","volume":"589","author":"Schneider","year":"2015","journal-title":"FEBS Lett."},{"key":"10.1016\/j.tem.2020.02.002_bb0365","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.abb.2008.11.008","article-title":"Human sodium\/inositol cotransporter 2 (SMIT2) transports inositols but not glucose in L6 cells","volume":"481","author":"Lin","year":"2009","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.tem.2020.02.002_bb0370","doi-asserted-by":"crossref","first-page":"G1300","DOI":"10.1152\/ajpgi.00422.2007","article-title":"SMIT2 mediates all myo-inositol uptake in apical membranes of rat small intestine","volume":"293","author":"Aouameur","year":"2007","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.tem.2020.02.002_bb0375","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/09513590903366996","article-title":"Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women","volume":"26","author":"Raffone","year":"2010","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.tem.2020.02.002_bb0380","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.3168\/jds.2013-7461","article-title":"In vitro iron absorption of alpha-lactalbumin hydrolysate-iron and beta-lactoglobulin hydrolysate-iron complexes","volume":"97","author":"Wang","year":"2014","journal-title":"J. Dairy Sci."},{"key":"10.1016\/j.tem.2020.02.002_bb0385","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.foodhyd.2014.10.017","article-title":"Alpha-lactalbumin: a new carrier for vitamin D3 food enrichment","volume":"45","author":"Delavari","year":"2015","journal-title":"Food Hydrocoll."},{"key":"10.1016\/j.tem.2020.02.002_bb0390","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.2174\/1567201815666180509102641","article-title":"Alpha-lactalbumin effect on myo-inositol intestinal absorption: in vivo and in vitro","volume":"15","author":"Monastra","year":"2018","journal-title":"Curr Drug Deliv."},{"key":"10.1016\/j.tem.2020.02.002_bb0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10565-005-0085-6","article-title":"The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics","volume":"21","author":"Sambuy","year":"2005","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.tem.2020.02.002_bb0400","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/17425247.2013.745509","article-title":"Paracellular drug absorption enhancement through tight junction modulation","volume":"10","author":"Lemmer","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.tem.2020.02.002_bb0405","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-018-0411-2","article-title":"Effects of myo-inositol plus alpha-lactalbumin in myo-inositol-resistant PCOS women","volume":"11","author":"Montanino Oliva","year":"2018","journal-title":"J Ovarian Res."}],"container-title":["Trends in Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104327602030031X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104327602030031X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:40:45Z","timestamp":1760906445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104327602030031X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S104327602030031X"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2020.02.002","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inositols in Polycystic Ovary Syndrome: An Overview on the Advances","name":"articletitle","label":"Article Title"},{"value":"Trends in Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tem.2020.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}